A Phase I, Open-label, Dose-Escalation and Dose-expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of HC006 in Advanced Solid Tumor Subjects
Latest Information Update: 20 Mar 2024
At a glance
- Drugs HC 006 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors HC Biopharma
- 20 Mar 2024 New trial record